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Abstract
Interleukin 1 (IL-1) is an inflammatory cytokine that helps the immune system fight
disease.  The inflammatory action of IL-1 is regulated by the naturally occurring interleukin 1
receptor antagonist (IL-1ra).  IL-1ra contains one N-linked glycosylation site and is expressed in
humans in both glycosylated and non-glycosylated forms.  The one current IL-1ra drug available
(Kineret®) is expressed in Escherichia coli as a non-glycosylated form.  Because of this, most
studies of IL-1ra have been done with the non-glycosylated form and the effects of glycosylation
have not been studied.  This research attempts to study the effects of the glycosylation of IL-1ra
with its binding to the interleukin 1 receptor type 1 (IL-1R1).  Both IL-1R1 and IL-1ra were
expressed in a glycosylation deficient strain of Pichia pastoris.  In-vitro binding experiments
between the two proteins were studied using both biolayer interferometry and size exclusion
chromatography.  Due to the long dissociation rate between IL-1ra and IL-1R1, biolayer
interferometry was an unfeasible method.  Size exclusion chromatography, however, proved to
be a promising tool to study binding.  Initial experiments with non-glycosylated IL-1ra showed a
potential KD of 1.7 nM.  Future studies need to be done using the glycosylated form of IL-1ra to
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Interleukin 1 (IL-1) signaling is inhibited by the competitive binding of the interleukin 1
receptor antagonist (IL-1ra) to the interleukin 1 receptor (IL-1R). IL-1 is an inflammatory
cytokine that helps the immune system fight off disease.1 IL-1 plays a role in both the innate and
adaptive immune system.  IL-1 can induce an inflammatory signal leading to inflammation, fever
and immune cell recruitment.  It can induce T cell proliferation so it also has a role in the
adaptive immune system.2 High levels of the IL-1 or low levels of IL-1ra can lead to
autoinflammatory disease.  In humans, IL-1ra is produced in both a glycosylated form and a non-
glycosylated form. A non-glycosylated IL-1ra drug (Kineret®) has been developed to help
regulate IL-1 signaling.  Various binding studies of IL-1ra to IL-1R1 have been done in cell
based assays - an in vitro cell based assay,3 a competition assay using IL-1α, IL-1β, or IL-1ra
with IL-1R1 and IL-1R2,4 a competition assay between IL-1α or IL-1β and IL-1ra for binding to
IL-1R1,5 and cell proliferation assays.6 Studies of the effect of glycosylation on the binding
between IL-1ra and IL-1R1 have not been attempted. The objective of this thesis is to determine
the effect of glycosylation on the binding between IL-1R1 and IL-1ra.
Background
Interleukin 1 (IL-1)
IL-1 is a cytokine about 17.5 kDa in size and consists of two main forms, IL-1α and IL-
1β.7 IL-1α is not secreted in the mature form from monocytes.  It is synthesized in the cytosol
when associated with cytoskeletal structures and remains in the cytosol as an active precursor.
When the cell dies it is released and the precursor can be cleaved by extracellular proteases.  IL-
1α is usually found in circulation during severe disease. IL-1β differs in that it is not active as a
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precursor and becomes active after cleavage by a protease and is then secreted. When the cell
encounters an endotoxin such as LPS, transcription of pro-IL-1β occurs.1 Before secretion, pro-
IL-1β is cleaved by an intracellular cysteine protease (caspase-1) to form the mature form of IL-
1β. Monocytes constitutively produce caspase-1 while macrophages require a stimulus to
produce it.8 After cleavage IL-1β is passively secreted from the cell and can bind with IL-1R1
throughout the body. Both of these forms bind to the interleukin 1 receptor (IL-1R). In the body
there are two forms of receptor, interleukin 1 receptor type 1 (IL-1R1) and interleukin 1 receptor
type 2 (IL-1R2) that can bind IL-1α, IL-1β, or IL-1ra.
Interleukin 1 receptor type 1 (IL-1R1)
IL-1R1 is an 80 kDa receptor with an extracellular 40 kDa region. When IL-1 binds to
IL-1R1 it forms a heterotrimeric complex with the interleukin-1 receptor accessory protein (IL-
1RAcP).9 This complex promotes a signaling cascade leading to the activation of nuclear factor-
κB (NF-κB), c-Jun N-terminal kinases (JNKs), and p38 mitogen-activated protein kinase
pathways.10 These induce the expression of other proinflammatory proteins such as IL-6 and IL-
8.10 These events lead to an inflammatory signal recruiting immune cells and causes fever and
vasodilation to help fight infection. Endothelial cells are induced by the IL-1 signal and produce
adhesion molecules on their surface allowing recruitment of immune cells.11 Cell surfaces can
be densely populated with IL-1R1 receptors; however, IL-1β only needs to bind to a few
receptors on the surface to initiate an inflammatory response.2 So small changes in the amount
of IL-1β in the body can lead to disease.
IL-1R1 is heavily glycosylated with six potential glycosylation sites. It was shown that
removing the glycans from IL-1R1 leads to a reduction in binding affinity of IL-1α to IL-1R1.
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The same researchers showed that glycosylation of IL-1R1 was required for proper transport to
the cell membrane.12
IL-1R2 is able to bind both IL-1α and IL-1β but lacks a cytoplasmic domain and does not
produce an inflammatory signal. For this reason, IL-1R2 is thought to be a decoy receptor
sequestering IL-1β so it is unable to bind to IL-1R1.1
Because of the amount of cell receptors and the small amount of IL-1β that is needed to
produce an inflammatory signal, regulation of IL-1β is important. Other than regulation by IL-
1R2, an important form of regulation comes from a naturally occurring antagonist (IL-1ra).
Interleukin 1 receptor antagonist (IL-1ra)
IL-1 binding is regulated by a naturally occurring interleukin 1 receptor antagonist (IL-
1ra). Human IL-1ra has a naturally occurring N-linked glycosylation site and is produced as a
mixture of glycosylated and non-glycosylated forms; however, the type of glycosylation is
unknown.5 The reason that the body produces both forms of IL-1ra is unknown. It is believed
that the glycosylation of IL-1ra does not affect the ability of IL-1ra to inhibit IL-1 inflammatory
response.  However, it is also believed that glycosylation of IL-1ra might protect the protein
from degradation in the extracellular space.13 The glycosylated form of IL-1ra is approximately
19 kDa while the non-glycosylated form is approximately 17 kDa.
Regulation occurs because when IL-1ra binds, it creates a conformational change that
does not allow binding of the accessory protein and subsequent signaling. IL-1ra has been
shown to bind to all three domains of IL-1R1 while IL-1β has been shown to bind to only two,
leading to the change in conformation.9, 14 It has also been shown that while both IL-1ra and IL-
1β have similar binding affinities (205 pM for IL-1α/IL-1β versus 115 -140 pM for IL-1ra using
in vitro cell based assays)3; a 10 to 100 fold excess of IL-1ra is required to inhibit IL-1β.2 This
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inhibition is due to cells having a large number of receptors on the surface. Since only a few
receptors are required to initiate an inflammatory response, IL-1ra must be bound in excess to the
surface receptors to inhibit the inflammation signal.2
IL-1 associated inflammatory diseases
While IL-1 signaling is important in helping the body fight infection, high levels of IL-1β
or low levels of IL-1ra have been linked to many diseases. One of the more noted diseases is
rheumatoid arthritis. In rheumatoid arthritis a high level of IL-1β in the synovial fluid leads to an
attack of collagen and inflammation in the joints.  This attack of collagen damages the bone.  IL-
1ra drugs were created to help regulate IL-1β signaling.15
Cryopyrin-associated periodic syndromes (CAPS) are a class of diseases that cause
periodic fever syndromes due to mutations resulting in constitutive activation of caspase-1 and
excessive secretion of IL-1β.11 These diseases include Muckle-Wells syndrome, familial cold
autoinflammatory syndrome (FACS) and neonatal-onset multisystem inflammatory disease
(NOMID). FACS symptoms such as a rash, headache, and fever occur after the skin is exposed
to cold.  Muckle-Wells syndrome leads to rash like lesions without the skin being exposed to
cold.  NOMID is a disease that causes chronic inflammation resulting in a skin rash present from
birth and tissue damage of the nervous system and joints.16
IL-1ra based drugs
The only IL-1ra drug developed so far has been Kineret® (anakinra) made by the
Swedish Orphan Biovitrum (Sobi).  Kineret® is a non-glycosylated form of IL-1ra expressed in
E. coli15 and is used to treat both rheumatoid arthritis and NOMID. Kineret® is given in 100 mg
doses by subcutaneous injection once a day.15 Studies have shown that systemic inflammation
was reduced with anakinra including reduction in joint destruction.17 The half-life of the drug is
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short, around 4-6 hours.15 Because of the large injection needed and once a day dose, injection
site inflammation is common and patient compliance difficult.
Previous IL-1R1 binding studies and methods
Previous binding studies have been done in cell based assays using radiolabeled protein.
Dripps et al. did binding studies using 35S-IL-1ra, 125I-IL-1α and murine thymoma cell line
EL4.IL-2 cells at 4oC.  Cell bound IL-1ra was measured and a Scatchard plot was created to
determine binding.  This research gave a reported KD of 205 pM for IL-1α and 115-140 pM for
IL-1ra.3
A competition assay between IL-1ra and IL-1β binding to IL-1R1 was performed by
Bienkowski et al.5 They used the human monocyte cell line THP-1 to produce IL-1ra and did
competition assays by measuring the inhibition of 50 pM 125I-IL-1β on YT cells. They found
IC50 values from 0.60 to 1.15 nM for IL-1ra displacing IL-1β.
A competition assay using surface plasmon resonance (SPR) was created using both IL-
1R1 and IL-1R2 from synovial fluids immobilized on a BIAcore chip and introducing varying
concentrations of either IL-1ra, IL-1α, or IL-1β at room temperature.4 It was found that IL-1β
bound tighter to IL-1R2 than either IL-1α or IL-1ra and that IL-1ra bound tighter to IL-1R1 than
either IL-1α or IL-1β.4
An inhibition assay was performed by Takii et al.6 Various concentration of IL-
1ra was used to inhibit 1U/mL of IL-1 induced cell growth of D10N4M cells at 37
oC.  These
cells were grown for three days in the presence or absence of IL-1ra. They were able to find an
IC50 of around 11 nM.
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Binding studies using in vitro cell based assays possess some problems.  Internalization
of the complex could lead to higher binding affinities.  Also, interactions with other receptors on
the cell surface might lead to altered binding.
Conclusion
IL-1ra is a naturally occurring antagonist produced by the body in both glycosylated and
non-glycosylated forms.  IL-1ra is able to bind to IL-1R1 and prevent an inflammatory signal.
Many IL-1 associated diseases can be treated using non-glycosylated IL-1ra.  Binding studies
done using in vitro cell based assays have shown a reported KD of 115-140 pM for IL-1ra.  These
binding studies present some problems and have not measured the effects of IL-1ra
glycosylation.  This thesis attempts to develop a binding assay to determine the effects of
glycosylation of IL-1ra on the binding to IL-1R1.
Experimental
Materials and Methods
Restriction enzymes (Not I, Xho I, Pme I) were obtained from New England BioLabs®.
The plasmid pPICzαA, competent Top 10 F’ Escherichia coli, and Pichia pastoris were obtained
from Invitrogen™. Yeast nitrogen base was obtained from Sunrise Biosciences. Tryptone and
yeast extract were obtained from Becton Dickinson.  General chemicals were obtained from
Sigma-Aldrich or Fisher Scientific. The nitrocellulose membrane used for the dot blot was a
BioTrace™ NT pure nitrocellulose transfer membrane from Pall Corporation. Antibodies used
for the dot blot (Pierce™ 6x His epitope tag and Pierce™ Goat Anti-Mouse IgG (H+L), Alkaline
Phosphatase conjugated) and 1-Step™ NBT/BCIP used for development were obtained from
Thermo Scientific. Protein samples were reduced with 10 mM dithiothreitol (DTT).  The protein
samples were analyzed using LC/MS. Samples were desalted on a reverse phase C4 column,
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50mm, 4.6mm I.D. (Vydac 214MS, 300 A pore size, 5 um particle size) using a Agilent 1200
series Liquid Chromatography system. The solvents used were A (99.9%H2O, 0.08% formic
acid, 0.02% TFA) and B (99.9% acetonitrile, 0.08% formic acid, 0.02% TFA). A gradient was
developed from 5%B to 90%B in 7 min with a flow rate of 0.5ml/min. They were then analyzed
by electrospray ionization mass spectrometry using a Agilent 6520 Quadrupole Time-of-Flight
(Q-TOF) system. The instrument was operated in positive ion mode and spectra were acquired
covering mass range from 300-3000 m/z with acquisition rate of 1 spectra/second. BioConfirm
software Qualitative Analysis (Agilent, Version B.03.01) was used to collect data. Protein MW
was calculated using Maximum Entropy Deconvolution function within the software.
Hydrophobic interaction chromatography was done using a GE Healthcare Life Sciences
HiPrep™ Phenyl FF HIC column. An 80 mL column was made using SP-Sepharose fast flow
resin from GE Healthcare Life Sciences. UV/Vis was done using a Beckman Coulter™ DU®
530 UV/vis Spectrophotometer. Biolayer interferometry was done using a fortéBIO BLItz®
system with fortéBIO Dip and Read™ Streptavidin Biosensors and analyzed using BLItz Pro™
Software 1.1.  Size exclusion chromatography was done using a 300 x 7.8 mm Yarra 3 um SEC
3000 and Shimadzu HPLC system.
Production of expression plasmid for IL-1R1 containing a C-terminal
sortase/histidine tag
The extracellular domain of IL-1R1 was cloned by conducting PCR using primers (3’-
GCCGCGCGCGCGGCCGCTTAATGATGATGGTGGTGGTGTCCTCCAGTTTCTGGCAAT
CCCTTCTGGAAATTAGTGACTGGATATATT -5’ and 5’-
GGCCCGCTCGAGAAAAGACTGGAGGCTGATAAATGCAAGG-3’) and the cDNA for IL-
1R1 from the Mammalian Gene Collection (MGC:79368)18 inserted as a template.  The PCR
product was restriction digested by Not I and Xho I and ligated into the plasmid pPICzαA using
8
DNA ligase.  The pPICzαA with the inserted DNA formed the new plasmid pPICzαA-IL-1R1-
LPETGGG-his6, was transformed into competent Top 10 F’ E. coli using electroporation,19 and
then selected for on LB-zeocin plates (1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1% (w/v)
NaCl, 1.5% (w/v) agar, 25 μg/mL zeocin). The plasmid was purified and the insert was
confirmed by DNA sequencing.  The plasmid was linearized with PmeI and transformed into a
competent P. pastoris strain with deleted OCH1 using electroporation and selected for using
YPD-zeocin plates (2% (w/v) tryptone, 1% (w/v) yeast extract, 2% (w/v) dextrose, 2% (w/v)
agar 100 μg/mL zeocin). The plates contained multiple colonies. Ten colonies were picked and
screened for higher expression.  The colonies were transferred into 2 mL cultures.  Once dense,
the cultures were induced with methanol (0.5% (v/v) every 12 hours) for 3 days.  After three
days each culture was screened for IL-1R1 expression by a dot blot.
The dot blot was created by pipetting 5 μL of the induced cultures onto a nitrocellulose
membrane.  The membrane was allowed to dry and then blocked with 20 mL of TTBS (20 mM
Tris-HCl, 500 mM NaCl, 0.05% tween 20) and 5% milk for 1-hour at room temperature (22oC).
After 1-hour 5 μL of the primary antibody was added (6x-His Epitope tag) to the blocking
solution and allowed to incubate for 6 hours at 4oC. The blocking/antibody solution was
removed and the membrane was washed with TTBS.  20 mL TTBS with 5% milk was added to
the membrane with 5 μL of the secondary antibody (alkaline phosphatase conjugated anti-mouse
IgG (H+L) made in goat) and incubated at 4oC for 6 hours.  The blocking/antibody solution was
again removed and washed with TTBS and the blot was developed using NBT/BCIP. The blot
developed a purple color for the His tagged proteins. A frozen stock was prepared from the
highest expressing colony.
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Expression of IL-1R1 containing a C-terminal sortase/histidine tag
A 2 mL culture of P. pastoris transformed with pPICzαA-IL-1R1-LPETGGG-his6 was
grown from the frozen stock in YPD media (2% (w/v) tryptone, 1% (w/v) yeast extract, 2%
(w/v) dextrose, 100 μg/mL zeocin) at 25oC for 3 days and transferred to a 50 mL flask containing
YPD media.  This 50 mL culture was grown for 2 days at 25oC and transferred into a 1 L spinner
flask containing culture media (1% (w/v) yeast extract, 2 % (w/v) tryptone, 1.34% yeast nitrogen
base, 2% (w/v) dextrose, 0.1 M potassium phosphate, pH 6.0, 4 x 10-3 % (w/v) histidine, 4 x 10-5
% (w/v) biotin). The 1 L culture was grown at 25oC with air being introduced at 3 L/min.  After
3 days the culture was induced with methanol for an additional 3 days (0.7% v/v methanol every
12 hours).  The culture was centrifuged at 6,693 G for 20 min and the supernatant was collected.
The supernatant was adjusted to a pH of 7.8, refrigerated overnight at 4oC to allow for any
precipitate to settle and filtered using Whatman 1 filter paper.  After all precipitate was removed,
the supernatant was concentrated from 1 L to 200 mL using a Vivaflow 200 10,000 MWCO
concentrator.  Purification of IL-1R1-LPETGGG-his6 was done using a Ni-NTA agarose
column.  First the column was equilibrated with equilibration buffer (50 mM potassium
phosphate, pH 7.8). Next the concentrated supernatant was loaded and collected.  The column
was then washed until the absorbance reached baseline using wash buffer (50 mM potassium
phosphate, pH 7.8, 500 mM NaCl, 5% glycerol, 20 mM imidazole). Finally the protein was
eluted using elution buffer (50 mM potassium phosphate, pH 7.8, 250 mM imidazole).  During
elution, 6-10 mL fractions were collected by hand based on the UV chromatogram and dialyzed
in 20 mM potassium phosphate buffer, pH 7.5, for storage at -20oC.  The fractions were checked
using SDS-PAGE (Figure 1) to determine which ones contained protein and then confirmed
using mass spectrometry (Figure 2). The expected and observed masses are given in Table 1.
PNGaseF was used to deglycosylate the protein to check for the full length protein. The protein
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concentration was calculated using Beer’s Law with an absorbance at 280 nm, path length of 1
cm, and extinction coefficient of 52830 M-1cm-1.  The extinction coefficient was found using the
primary amino acid sequence.20 The expression protocol gave a yield of 6 mg/L.
Secondary purification of IL-1R1 by hydrophobic interaction chromatography
The fractions containing protein were pooled together and prepared for hydrophobic
interaction chromatography (HIC) by adding solid ammonium sulfate to a final concentration of
1M. About 4 mg of IL-1R1 was loaded onto a 20 mL HiPrep™ Phenyl FF HIC column pre-
equilibrated with buffer A (50 mM sodium phosphate, 1 M ammonium sulfate). The protein was
eluted with a gradient of 10 column volumes starting with 100% buffer A and finishing with
100% buffer B (50 mM sodium phosphate).  5 mL fractions were collected and checked by SDS-
PAGE.  The fractions containing protein were pooled together and dialyzed into PBS buffer (50
mM sodium phosphate, 150 mM NaCl, pH 7.4) for binding experiments and stored at -20oC. 1.8
mg of protein was obtained after HIC purification for a yield of 44% for this purification step.
Expression of IL-1ra
Human IL-1ra was previously cloned into pIL-zαA and transformed into P. pastoris
SMD1168H.21 Glycosylated and non-glycosylated IL-1ra was produced in yeast and purified as
described by Hamilton et al.21 The purification chromatogram is shown in Figure 3. The
fractions were checked for protein by SDS-PAGE (Figure 4a) and confirmed using mass
spectrometry (Figure 4b). The expected and observed masses are given by Table 2. After
confirmation, the fractions containing glycosylated IL-1ra were pooled together and the fractions
containing non-glycosylated IL-1ra were pooled together.  The concentrations were determined
by Beer’s Law using the extinction coefficient for IL-1ra of 15470 M-1cm-1 calculated from the
primary amino acid sequence.20
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Sortase Reactions
Sortase mediated ligation of biotin to IL-1R1
The sortase enzyme was expressed previously by a lab member and used to ligate GGG-
EDA-biotin made by another lab member (Reaction Scheme 1, compound 2) to IL-1R1-
LPETGGG-his6 (Reaction Scheme 1, compound 1). IL-1R1 was prepared for sortase ligation
by dialyzing the protein in sortase buffer (50 mM tris, 150 mM NaCl, pH 7.5).  A 1.5 mL sortase
reaction was performed using 3 μM sortase, 3 μM IL-1R1, 2 mM CaCl2, 1 mM GGG-EDA-
biotin. The reaction scheme is provided in Reaction Scheme 1 with the completed reaction
yielding IL-1R1-biotin (Reaction Scheme 1, compound 3). The reaction was incubated at 37oC
for 24 hours and quenched with 10 mM EDTA.22 Completion of the reaction was checked using
mass spectrometry (Figure 5). The expected and observed masses are shown in Table 3.  The
yield was 51% based on the peak intensity found in the mass spectrum. Following confirmation
of the completed reaction the reaction was dialyzed in PBS buffer for storage and future binding
studies.
Sortase mediated ligation of fluorescein to IL-1R1
IL-1R1 with a sortase tag (Reaction Scheme 2, compound 1) was dialyzed into sortase
buffer for sortase ligation.  A 500 μL reaction was performed (2.5 μM sortase, 2.5 μM IL-1R1, 1
mM GGG-EDA-5(6) carboxyfluoroscein (Reaction Scheme 2, compound 2) made by a lab
member, 2 mM CaCl2). The reaction scheme is provided in Reaction Scheme 2 with the
completed reaction yielding IL-1R1-FL (Reaction Scheme 2, compound 3). The reaction was
incubated at 37oC for 24 hours then quenched with 10 mM EDTA.
Sortase mediated ligation of fluorescein to IL-1ra
A lab member ligated fluorescein to IL-1ra in a 3 mL reaction. Reaction Scheme 3
shows the reaction of IL-1ra with a sortase tag (Reaction Scheme 3, compound 1) being ligated
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to GGG-EDA-fluorescein (Reaction Scheme 3, compound 2) yielding IL-1ra-FL (Reaction
Scheme 3, compound 3). After the ligation, the product was purified using a Ni-NTA agarose
column. To remove sortase and excess fluorescein the reaction was dialyzed after confirmation
from mass spectrometry (Figure 6). The reaction gave a yield of 88% fluorescently labeled
protein from analysis of the peak intensities from the mass spectrum. Table 4 shows the expected
and observed masses.
During the course of purification and dialysis the protein becomes more dilute and could
have some loss.  Because of this potential change in IL-1ra concentration, the concentration had
to be recalculated.  The dye can contribute to the absorbance at 280 nm so the concentration of
the dye has to be adjusted for when calculating the concentration of IL-1ra according to the
following equation:23
Aprotein= A280 – Amax(CF)
Aprotein= A280 – A494(0.30)
A correction factor for fluorescein was found by Life Technologies to be 0.30 for
fluorescein and the maximum wavelength for absorbance for fluorescein is 494 nm.23 Using this
equation, the absorbance at 280 nm and 494 nm was found and the absorbance of the protein was
calculated. After calculating protein absorbance, Beer’s Law can be used to find the
concentration of the protein, with an extinction coefficient for IL-1ra of 15470 M-1cm-1
calculated from the primary amino acid sequence.20
Binding studies of IL-1ra to IL-1R1 using biolayer interferometry
Biotin labeled IL-1R1 and both glycosylated and non-glycosylated IL-1ra were dialyzed
into PBS buffer. The biolayer interferometry (BLI) binding experiment was performed using a
fortéBIO BLItz® system with fortéBIO Dip and Read™ Streptavidin Biosensors and analyzed
using BLItz Pro™ Software 1.1.  The biosensors were hydrated with binding buffer (PBS buffer,
13
1 mg/mL BSA) for 30 minutes. BSA was used to block any non-specific binding interactions
with the biosensor.  The biotin labeled IL-1R1 was loaded onto the tip until a loading level of 0.5
nm was achieved.  The tips were washed using PBS containing 1 mg/mL BSA.  After the tips
were washed the binding experiment was carried out.  First, a 30-second baseline using binding
buffer was done. Then glycosylated IL-1ra at various concentrations (500, 250, 125, 62, 31, 15
nM) was loaded for an association time of 5 minutes. Finally, a 30-minute dissociation was done
using binding buffer. A 30-minute dissociation time was decided after increasing the
dissociation times due to the observed slow kinetics of dissociation. Two experiments were
carried out to test for dissociation over longer times. One experiment used a dissociation time of
2 hours and a second experiment used a dissociation time of 8 hours.
Binding studies of IL-1ra to IL-1R1 using size exclusion
Size exclusion experiments were carried out using a 300 x 7.8 mm Yarra 3 um SEC 3000
and Shimadzu HPLC with a flow rate of 1 mL/min of PBS buffer for 25 minutes. Between each
run the loading tip was washed with water for 15 seconds. The column could separate proteins
between 244 Da and 670,000 Da. Experiments were done using either the fluorescently labeled
IL-1ra (IL-1ra-FL) or IL-1R1 (IL-1R1-FL). Experiments using IL-1R1-FL were done using 500
nM IL-1ra and 3 μM IL-1R1-FL. These experiments were not continued due to inadequate
resolution between the complex and IL-1R1-FL. Experiments using IL-1ra-FL were carried out
by keeping the IL-1ra constant (500 pM) while adding various concentrations of IL-1R1 (5000,
2500, 1250, 625, 312.5, 156.25, 78.125 pM). While these concentrations were higher than the
reported KD,
3 these concentrations were chosen because it produced a sufficient fluorescent
signal that could be used to track the binding of IL-1ra over the course of the experiment.
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IL-1ra-FL and IL-1R1 were both dialyzed into PBS buffer.  IL-1ra-FL was diluted from
the concentrated stock to 1 nM.  IL-1R1 was diluted initially from concentrated stock to 10000
pM and then serially diluted to the final concentrations.  The two protein solutions were mixed in
a 1:1 ratio and the final concentration of each protein was reached.  The solutions were incubated
at room temperature (22oC) for 5 hours before injecting 50 μL onto the size exclusion column. A
single size exclusion experiment for one sample lasted 25 minutes.  Between each experiment
the loading tip was rinsed with water for 15 seconds. The protein was detected using a
fluorescence detector with an excitation wavelength of 494 nm and an emission wavelength of
521 nm. The peak areas for both the unbound IL-1ra and bound IL-1ra were calculated. A
binding curve was created using the percent of bound IL-1ra versus the concentration of
receptor. Some experimental issues arose that will be discussed further in the Results and




The extracellular region of IL-1R1 (MGC: 79368)18 was cloned with a C-terminal sortase
tag and polyhistidine tag (IL-1R1-ST-HIS6) (Reaction Scheme 1, compound 1) and subcloned
into pPICzαA. This region was expressed because it was soluble and needed for binding. The
pPICzαA vector allowed for expression of the IL-1R1 construct under control of the methanol-
inducible Alcohol Oxidase 1 promoter. Additionally, the construct was cloned in frame of the α-
mating factor from Saccharomyces cerevisiae, allowing for secretion of the construct. A Kex2
site between the α-factor and the IL-1R1 construct allowed for cleavage of the α-factor from the
polypeptide.24 The construct was confirmed by DNA sequencing and then transformed into P.
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Pastoris. IL-1R1 contained both the sortase cleavage site LPETGGG and six C-terminal
histidines.  The sortase recognition site was added so the IL-1R1 could be ligated with other tags
for experiments.  In the case of the experiments done in this report, both biotin and fluorescein
were added to the C-terminus to be used in the BLItz and size exclusion experiments.  The
polyhistidine tag allows for purification of IL-1R1 using Ni-NTA agarose chromatography resin.
Higher expressing colonies were screened for with a dot blot from 2 mL cultures. The highest
expressing colony was selected based on the intensity of the purple color of the blot. After
purification the concentration and purity of the protein can be determined. The expression of IL-
1R1 was done in a glycosylation deficient strain of P. pastoris and yielded an average of 6 mg/L.
The glycosylation deficient strain allowed for the production of glycoproteins with high mannose
glycans ranging from Man8GlcNAc2 to Man20GlcNAc2.
As can be seen in Figure 1a the purity of IL-1R1 from purification by Ni-NTA agarose
chromatography is not high. The SDS-PAGE shows broad bands at around 34 kDa in Lane 1
and around 45 kDa in Lane 2 with smaller, less intense bands indicating impurities throughout
the gel. These impurities could be proteolyzed IL-1R1 or other proteins produced by P. pastoris
that were bound to the Ni-NTA resin. Lane 3 contains glycosylated IL-1R1 while Lane 2 shows
non-glycosylated IL-1R1.  PNGase F was used to remove N-linked glycans from IL-1R1 to
simplify analysis of the protein by SDS-PAGE and mass spectrometry.  This will decrease the
molecular weight from approximately 45,000 Da for fully glycosylated (6 sites occupied) IL-1R1
to 38186 Da for non-glycosylated IL-1R1. PNGase F can be seen on Lane 2 as a faint band
around 35 kDa located between the two darker bands around 40 kDa and 30 kDa.  The two
darker bands show up in both the glycosylated IL-1R1 lane and the lane containing PNGase F
treated IL-1R1.  This leads to the idea that the lower band is proteolyzed IL-1R1. IL-1R1 needs
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to be pure for binding experiments.  Any impurities could affect the calculated concentration of
IL-1R1 leading to false binding curves.  For BLI the concentration of IL-1R1 is as not important
as will be discussed in the section containing binding studies using BLI. However, when doing
binding studies using size exclusion, the concentration of IL-1R1 is important.
Because of the impurities seen in Figure 1a, a second purification step was performed.
Hydrophobic interaction chromatography (HIC) using a HiPrep™ Phenyl FF HIC column was
performed as this second purification step.  Fractions from the HIC purification were checked
using SDS-PAGE to determine purity and then pooled together. The HIC purification diluted the
samples to 0.02 mg/mL for a yield of 1.8 mg or 44%. Because the sample was dilute, the sample
was concentrated 10 fold to look for any impurities (Figure 1b). Figure 1b shows, when
compared to Figure 1a, that the impurities were removed by HIC.  There appear to be no
shadows above or below the main band.
Table 1 shows the expected and observed masses found in the mass spectrum located in
Figure 2. To determine if the full length protein was expressed and no proteolysis has occurred,
the protein was observed using mass spectrometry.  For this step the protein was reacted with
PNGaseF, an enzyme that cleaves N-linked glycans.  During this reaction asparagine is
converted to aspartic acid, increasing the mass by 1 Da.  In the case of IL-1R1 the expected
deglycosylated mass is 38186 Da.  If all potential glycosylation sites were occupied, then after
deglycosylation the expected mass would be 38192 Da. However, the peak shown in Figure 2a
is 38189 Da indicating removal of 3 glycans.  Figure 2b shows IL-1R1 with glycosylation.
Figure 2b and Table 1 show that four to six sites are occupied. The glycosylation
deficient strain of yeast used gives high mannose glycans. The masses found in Figure 2b shows
that 3, 4, 5, and 6 N-linked glycosylation sites are occupied.  Each of these sites contains high
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mannose glycoforms starting at Man8GlcNAc2 and going to Man15GlcNAc2 for some occupied
sites. This mass spectrum shows that all 6 glycosylation sites can become occupied during yeast
expression; however, when all 6 sites were glycosylated, mannose phosphorylation was
observed.
Expression of IL-1ra
IL-1ra was cloned previously by Hamilton et al.21 The procedures for the purification of
glycosylated IL-1ra using SP-Sepharose and the yeast strain developed in the Hamilton paper
were used to express and purify glycosylated and non-glycosylated IL-1ra. These products will
be used in future studies when a working IL-1ra binding method has been developed.21
Figure 3 shows the UV chromatogram during the purification of IL-1ra using SP-
Sepharose as was described by the above purification procedure.  As is shown in the figure and
as was reported,21 the peak for glycosylated IL-1ra can be distinguished from the peak for non-
glycosylated IL-1ra.  The fractions associated with these peaks were checked on a gel and then
the glycosylated IL-1ra was pooled and non-glycosylated IL-1ra was pooled.  These were then
confirmed using mass spectrometry.  As can be seen in the gel (Figure 4a), the purity of both
forms of IL-1ra was high so no secondary purification step was needed.
Figure 4b shows the mass spectra for both non-glycosylated IL-1ra and glycosylated IL-
1ra while Table 2 shows the observed and expected masses. The table and mass spectrum show
that there is one occupied glycosylation site starting at Man8GlcNAc2 up to Man18GlcNAc2.
A 1 L yeast expression yielded 5.1 mg of non-glycosylated IL-1ra and 9.9 mg of




Sortase is a cysteine protease that cleaves between threonine and glycine in the sortase
recognition site (LPETG) to form a thioester intermediate between the substrate and enzyme.
Compounds containing an N-terminal glycine can act as a nucleophile to attack the thioester
bond, displacing the sortase enzyme, and forming a peptide bond between the substrate and
compound. Sortase mediated ligations are useful because they are site specific, can be used to
attach various labels (fluorescein, biotin), only require a C-terminal sortase tag, and the reactions
can be carried out under mild conditions (pH 7.5). The activity of the sortase enzyme, however,
is limited by the dependence of calcium. The product after ligation is also a substrate for the
enzyme that can make it difficult for completion of the reaction.22, 25
IL-1R1 sortase mediated ligation of biotin
IL-1R1 was cloned with a sortase recognition site (LPETG). GGG-EDA-biotin was
synthesized by another lab member. After sortase cleavage the GGG-EDA-biotin will ligate to
the LPET of the protein shown in Reaction Scheme 1. Figure 5 shows the mass spectrum of the
product of the sortase mediated ligation of biotin. The biotinylation of IL-1R1 gave us the
product IL-1R1-Biotin.
The mass spectrum shows five major peaks.  PNGaseF was added to remove the N-linked
glycans, however, incomplete glycosylation occurred.  Without removal of the glycans the mass
spectrum would be too cluttered to properly interpret the success of the reaction. Table 3 shows
the expected mass, observed mass, and peak intensities. Using the information in the table,
estimation of yield by comparing peak intensities of the product versus the starting material gave
a 51% yield.
19
Sortase mediated ligation of fluorescein to IL-1ra and IL-1R1.
GGG-EDA-5(6)carboxyfluorescein, synthesized by a lab member was ligated to IL-1ra
by another lab member.  The ligation of fluorescein to IL-1ra gave the product IL-1ra-fluorescein
(IL-1ra-FL).  In order to remove unreacted IL-1ra the protein was purified by a lab member on a
Ni-NTA agarose column.  The protein was then dialyzed in PBS buffer to remove unligated
fluorescein. Figure 6a shows the difference between purified IL-1ra-FL and the unpurified IL-
1ra. As can be seen at the bottom of Lane 1 there remains some unreacted fluorescein which is
not present in the purified form in Lane 2. Figure 6 shows the mass spectrum for the ligation of
fluorescein to IL-1ra. The reaction was not 100% complete with about an 88% yield based on
the peak intensities as shown in Table 4.  The final concentration of IL-1ra-Fl was 7 μM.
Fluorescein was also ligated to IL-1R1 and used for initial size exclusion experiments.
There was little resolution between the complex and IL-1R1 peaks so further experiments using
fluorescently labeled IL-1R1 were not conducted and additional purification was not required.
Binding experiments of IL-1ra to IL-1R1 using biolayer interferometry
BLI allows for the real time kinetic analysis of binding between two molecules.  BLI uses
a biosensor that is composed of glass fiber containing a bio-compatible layer at the tip.
Streptavidin is immobilized on the bio-compatible layer through a proprietary surface chemistry.
Streptavidin has a high binding affinity for biotin with a KD around 10
-14 M.   This allows for
immobilization of a biotinylated protein (IL-1R1) for binding studies with a protein in solution
(IL-1ra). White light is transmitted through the biosensor and then reflected back. The light is
reflected back from two interfaces, one is the bio-compatible layer/glass fiber interface and the
other is the solution and surface layer containing the bound protein.  The light reflected from
these two surfaces will have a different path length. An increase in path length results in
constructive or destructive interference between the two reflected light waves leading to an
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interference pattern monitored by the instrument and response measured as a shift in nm. A
sensor reads the initial interference pattern from the two light waves and can determine a
baseline before any addition of the biotinylated receptor. After addition of the receptor the path
length increases and a second baseline is recorded. Once this baseline is established IL-1ra can
be added. The formation of the IL-1ra/IL-1R1 complex further increases the path length and the
interference can be monitored over the course of association. At the end of association, buffer is
introduced causing dissociation of complex, decreasing the path length. The kinetic association
and dissociation rates are calculated by the instrument based on 1:1 curve fitting and the
corresponding association rate constant (ka), dissociation rate constant (kd), and dissociation
constant (KD) derived from the ratio of the rate constants can be found.
26 Figure 7 shows a
general scheme for how a BLI experiment using BLItz should look.
Initial binding experiments were conducted using concentrations of IL-1ra between 500
nM and 15.625 nM. IL-1R1 was loaded to a low level to prevent crowding of the biosensor
(Figure 8). These initial experiments were done to determine appropriate receptor loading,
association time, dissociation time, and how to remove non-specific binding.
Because non-specific binding occurs between the ligand and the biosensor, 1 mg/mL
BSA was added to all samples and buffers. Figure 9 shows how BSA affects both the baseline
(with no IL-1R1 added) and the association signal (with IL-1R1 added). With no BSA present
IL-1ra binds to streptavidin producing a small association curve.  When BSA was introduced as a
blocking agent, IL-1ra was unable to bind non-specifically to the biosensor. When the receptor
was introduced, addition of BSA had a slight effect on the binding.  The association of IL-1ra to
IL-1R1 produced a smaller signal than when no BSA was added.
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As was discussed previously the IL-1R1 sample was a mixture of biotinylated IL-1R1
and IL-1R1 with a histidine tag. This impurity was not a concern because only the biotinylated
IL-1R1 would bind to streptavidin biosensor. Because of this the protein did not undergo any
additional purification.
The association times and dissociation times were adjusted based on experiments.  The
association time was increased to 5 minutes to allow for equilibrium. As can be seen by the
binding curves there is little to no dissociation over the course of the experiment. Initially a 2-
minute dissociation time was used but the time was increased to 30 minutes due to the slow
dissociation.  This 30-minute dissociation time was used for an initial attempt at a binding curve
as seen in Figures 10a and 10b.
This slow dissociation gave variable KD’s.  The association constants remained relatively
close for each run 2.651 x 10-5 to 3.098 x 10-5 M-1s-1, while the dissociation constants varied
considerably between 1.53 x 10-4 and 4.767 x 10-4 s-1 with two samples providing no dissociation
at all. Figure 10a shows runs producing negative slopes indicating dissociation, while Figure10b
shows runs producing positive dissociation slopes, indicating something other than dissociation.
It is unknown why the positive slopes occur. This increase in signal could be due to the actual
dissociation rate being so small that baseline correction errors within the BLItz software could
overwhelm the measurement. Because an accurate kd could not be determined, any
determination of KD was impossible.
Since the dissociation rates measured in different experiments using a 30-minute
dissociation time were variable, experiments were done to test how long dissociation might take
to occur between IL-1ra and IL-1R1. These experiments used 2-hour and 8-hour dissociation
times instead of a 30-minute dissociation time. 8 hours was the maximum time the instrument
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collected data. Figure 11a shows the dissociation over 2 hours. As is shown in the figure, no
dissociation occurred over that time frame. Figure11b shows the dissociation over 8 hours. This
figure shows an abnormal dissociation curve over the time frame. The curve increases before
leveling off and then decreases, which is unexpected for a dissociation curve.
The information gained shows that using BLI to study the binding between IL-1R1 and
IL-1ra was impractical because the dissociation rate of the complex was too slow to measure
with the BLItz instrument. The slow dissociation of IL-1ra made it difficult to determine the KD
using kinetic measurements. Instead, the KD was investigated using an equilibrium binding
approach.
Binding studies of IL-1R1 to IL-1ra using size exclusion chromatography
The results from the use of BLI showed that the disassociation of IL-1ra is extremely
slow. In the experiment shown in Figure 11, even after eight hours there was no noticeable
dissociation occurring.  Because of this BLI is not suitable for studying this interaction and
another binding experiment had to be developed. A method that was thought to be appropriate
was size exclusion chromatography.  Size exclusion experiments using the Yarra SEC column
take about 9 to 11 minutes to elute proteins between 17 kDa and 70 kDa.  IL-1ra and the receptor
were not expected dissociate within this time frame because no dissociation was detected even
after 8 hours using BLI.  With the slow dissociation rate between IL-1ra and IL-1R1, the
complex would not dissociate over the course of a typical SEC experiment. Size exclusion
allows for the resolution between proteins of different sizes.  A size exclusion column has pores
that trap smaller molecules while the larger ones pass through.  IL-1ra is 17 kDa while IL-1R1 is
around 45 kDa.  When these two proteins bind they form a complex that is around 62 kDa.  This
size difference was able to be resolved by a Yarra SEC column.
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When performing the binding experiment the first step was to determine if IL-1ra or IL-
1R1 should be fluorescently labeled. The protein needed to be fluorescently labeled because at
the low concentrations used (500 pM) and a 50 μL injection volume, no protein could be
detected at 280 nm. The initial experiments were done before either protein was purified after
the sortase ligation so both fluorescently labeled proteins contain unknown impurities that can be
seen on the chromatograms.
As is shown in Figure 12a, the peak containing the complex can only be slightly resolved
from the peak containing uncomplexed fluorescently labeled IL-1R1. This is expected as the
difference in elution times on the Yarra column between the masses IL-1R1 (≈45 kDa) and the
complex (≈62 kDa) is not that great. This resolution was determined to not be enough to
continue doing size exclusion binding using fluorescently labeled IL-1R1. Because of this
fluorescently labeled IL-1R1 was not purified any further.
Size exclusion was able to separate the free form of fluorescently labeled IL-1ra from the
complex with higher resolution as shown in Figure 12b. Using the information from the two
experiments it was determined that using the fluorescently labeled IL-1ra and unlabeled receptor
was the best method.  The method used was to keep the fluorescently labeled IL-1ra (500 pM)
constant while varying the concentration of IL-1R1 (5000, 2500, 1250, 625, 312, 156, 78 pM).
Again, while the concentration of IL-1ra is well above the reported KD of 115-140 pM,
3 it was
chosen because it produced a good signal that could be used to detect the binding of IL-1ra to IL-
1R1 over the course of the experiment. This required additional purification of fluorescently
labeled IL-1ra to remove the unknown peaks. After purification of IL-1ra by the method
previously mentioned, a binding curve was created.
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The samples were incubated at room temperature (22oC) for 5 hours after being mixed
together. The concentrations of the components are low so the binding might take a long time to
reach equilibrium. A 5-hour incubation time was estimated after results from the BLI
experiments (Figure 13) using similar concentrations to what would be used in size exclusion
chromatography. Each sample was loaded onto the SEC column 3 times. Between each
experiment (25 minutes) is a loss of signal (Figure 14a). This loss was consistent between runs
of the same sample (Figure 14b); however, between runs of different samples the peak areas
varied. The binding experiment was conducted as described and peak areas were found for both
bound IL-1ra-FL and unbound IL-1ra-FL (Figure 15 and appendices).  These peak areas were
totaled (Table 5). This total peak area varied for different concentrations and was inconsistent.
The ratio of bound IL-1ra-FL to unbound IL-1ra between repeat injections, however, was
consistent.  Because of this, the percentage of IL-1ra-FL that was bound and the percentage that
was unbound could be used to create a binding curve (Figure 16).  These plots fit expected plots
for binding curves.27 As the receptor concentration is increased the percentage bound reaches an
equilibrium point. Using the information from these plots, the KD was found to be 1.7 nM.
Many difficulties were experienced during the experiments using size exclusion
chromatography.  The first issue was signal loss between runs.  This signal loss could be due to
adsorption onto the HPLC glass vial inserts.  To correct for this, deactivated glass inserts were
used. However, the deactivated glass caused even greater peak loss.  This loss could be due to
an increase in adsorption onto the deactivated glass or the deactivated glass causing a precipitate.
Another potential cause of loss could be from adsorption onto the column. When BSA was used
it was shown to help prevent signal loss (Figure 17).
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Future work
While the method presented proved to be a useful tool to study the binding of IL-1ra to
IL-1R1, future work needs to be done to complete the project. The reported KD for IL-1ra
calculated from a cell based assay was 115-140 pM.3 These experiments were conducted at 4oC,
which will give a different KD value than the experiments reported in the thesis at 22
oC. The
experiments using cell based assays differ from in vitro assays because the complex could
become internalized or have interactions with other receptors on the cell surface; however, these
assays are closer to how the binding occurs in the body.  These cell based assays could help us to
develop assays to see how the glycosylation of IL-1ra affects binding in more biologically
relevant systems.
The concentration of IL-1ra used for the size exclusion chromatography binding
experiment was 500 pM.  This concentration is almost 5 times greater than the reported KD.
3
This high concentration could lead to depletion of IL-1R1 leading to an overestimation of KD.
To prevent this, the concentration of IL-1ra needs to be 0.1 x KD (approximately 10 pM).
27 500
pM was chosen for convenience because it produced a good fluorescent signal that could be used
to observe binding.  The experiments done in this thesis used an injection volume of 50 μL.  To
obtain a good signal while using concentrations of IL-1ra around 10 pM, the injection volume
could be increased to an amount that produces an adequate signal, allowing for more accurate
binding data.
To reduce peak loss during the size exclusion experiment some changes may prove
useful.  As was discussed, using BSA as a blocking agent was shown to reduce peak loss.  Also,
the time duration of the experiment could be decreased.  The experiment was conducted over 25
minutes but all components eluted before 15 minutes.  Decreasing the experiment time could
result in less adsorption to the glass.
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An assay to study the binding between glycosylated IL-1ra and IL-1R1 needs to be
developed to compare with the results found for the binding between non-glycosylated IL-1ra
and IL-1R1.  This could be done with a competition assay between the already created non-
glycosylated IL-1ra-FL and glycosylated IL-1R1.  Another method that could be used would be
to add a sortase tag onto the C-terminus of glycosylated IL-1ra and fluorescently label the IL-1ra.
After glycosylated IL-1ra is fluorescently labeled, a binding curve could be performed using the
same methods already discussed.
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Figures
Figure 1: a) 12% SDS PAGE showing both glycosylated and nonglycosylated IL-1R1 after
Ni/NTA purification. Lane 1: Protein Marker Lane 2: IL-1R1 + PNGase F Lane 3: L-
1R1 b) 12% SDS PAGE gel of concentrated IL-1R1 after HIC purification Lane 1:
marker Lane 2: IL-1R1 Lane 3: IL-1R1 + PNGaseF.
a b
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Figure 2: a) Mass spectrum of IL-1R1 treated with PNGaseF. b) Mass spectrum of IL-1R1
showing glycosylation.
Table 1: Table showing expected and observed masses from the mass spectrum from Figure 2.
Expected Mass (Da) Observed Mass (Da)
Deglycosylated IL-1R1 38186 38189
3 sites occupied 43293 43299
4 sites occupied 44996 45003
5 sites occupied 46698 46706




































Figure 3: The purification using SP-sepharose was run according to the literature procedure.
The UV chromatogram shows the non-glycosylated and glycosylated peaks can be easily
resolved.
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Figure 4: a) 12% SDS PAGE of pooled IL-1ra fractions. Lane 1: Marker. Lane 2: Glycosylated
IL-1ra.  Lane 3: Non-glycosylated IL-1ra. b) Mass spectrum for glycosylated IL-1ra (top)






Table 2: Table showing the expected and observed masses from Figure 4.
Expected Mass (Da) Observed Mass (Da)













Figure 5: Mass spectrum of the reaction of the biotinylation of IL-1R1.








Biotinylated product 37632 37633 1.10 13.3
Biotinylated product
+ 1 Man8GlcNAc2
39334 39335 1.85 22.2
Biotinylated product
+ 1 Man9GlcNAc2
39496 39498 1.25 15.1
Unreacted product 38186 38188 2.20 26.5
Unreacted product +
1 Man8GlcNAc2
39888 39890 1.30 15.7
Unreacted product +
1 Man9GlcNAc2
40050 40053 0.60 7.2
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Figure 6: a) 12% SDS PAGE of IL-1ra-Fluorescein. Lane 1: unpurified IL-1ra-Fl. Lane 2:
Purified IL-1ra-Fl. b) Mass spectrum of the ligation of 5(6) carboxyfluorescein to IL-1ra.
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Figure 7: Diagram showing general BLItz experiment.  Step 1: Baseline using PBS buffer, 1
mg/mL BSA. Step 2: IL-1R1 loading. Step 3: Baseline using PBS buffer, 1 mg/mL BSA. Step 4:
IL-1ra association. Step 5: Dissociation with PBS buffer, 1 mg/mL BSA.
35
Figure 8: Loading of IL-1R1 to 0.5 nm to prevent crowding of the receptor on the biosensor.
AssociationBaseline
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Figure 9: a) nonspecific binding of IL-1ra.  Runs contained no IL-1R1 and 0.5 μM IL-1ra. Grey:
Run with 1 mg/mL BSA. Blue: Without BSA. b) Runs contained IL-1R1 and 0.5 μM IL-1ra.






Figure 10: a) BLItz curves showing binding for runs containing negative dissociation slopes.
Run 4: 500 nM. Run 8: 250 nM. Run 12: 125 nM. Run 24: 15 nM. b) BLItz curve showing
binding for runs containing positive dissociation slopes. Run 16: 62 nM. Run 20: 31 nM.
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Figure 11: a) 2-hour dissociation curve using BLItz. b) 8-hour dissociation curve using BLItz.
Association Dissociation
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Figure 12: a) 500 nM IL-1ra + 3 μM IL-1R1-FL. Blue line: 500 nM IL-1R1-FL no labeled IL-
1ra. Black line: Complex formed between 500 nM unlabeled IL-1ra and 3 μM IL-1R1-FL. b)
500 nM IL-1ra-FL + 3 μM IL-1R1. Pink line: 500 nM IL-1ra-FL and no unlabeled IL-1R1.
Black line: complex formed between 500 nM IL-1ra-FL and 3 μM unlabeled IL-1R1.



































































Figure 13: BLItz curve showing runs of low concentration over a 20-minute association time.
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Figure 14: a) 500 pM IL-1ra over 3 runs.  Each run is 25 minutes apart. Blue: Run 1. Black:
Run 2. Brown: Run 3. b) Chart showing the loss of fluorescent intensity of IL-1ra over the three
runs shown in Figure 14a.



























Figure 15: IL-1ra size exclusion run.  Blue: 500 pM IL-1ra-FL, no unlabeled IL-1R1. Black: 500
pM IL-1ra-FL, 5,000 pM unlabeled IL-1R1. Pink: 500 pM IL-1ra-FL, 2,500 pM unlabeled IL-
1R1.
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Table 5: Tables showing the peak area of bound and unbound and the percentage of bound and
unbound IL-1ra.
Conc (pM) Bound Unbound Total %Bound %Unbound
Run 1
78 0 1736 1736 0 100
156 58 2598 2656 2.18 97.82
312 108 1699 1807 5.98 94.02
625 574 2060 2634 21.79 78.21
1250 1036 1953 2989 34.66 65.34
2500 1783 399 2182 81.71 18.28
5000 3672 260 3932 93.39 6.61
Run 2
78 0 1534 1534 0 100
156 49 2305 2354 2.08 97.92
312 108 1182 1290 8.37 91.63
625 488 1713 2201 22.17 77.83
1250 975 1653 2628 37.10 62.90
2500 1486 338 1824 81.47 18.53
5000 3100 178 3278 94.57 5.43
Run 3
78 0 1349 1349 0 100
156 34 2062 2096 1.62 98.37
312 129 1008 1137 11.34 88.65
625 384 1318 1702 22.56 77.43
1250 886 1670 2556 34.66 65.33
2500 1496 328 1824 82.01 17.98
5000 2650 167 2817 94.07 5.92
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Figure 16: a) Chart showing percentage of protein bound versus the concentration of IL-1R1. b)
Chart showing the percentage protein bound versus the log of the concentration of IL-1R1.
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Figure 17: BSA added to complex of 500 pM IL-1ra-FL and 5,000 pM unlabeled IL-1R1.


















Reaction Scheme 1: Reaction scheme for the sortase mediated ligation of biotin to IL-1R1. 1)
IL-R1 containing a C-terminal sortase tag and poly histidine tag. 2) Triglycine ethylene diamine
biotin. 3) GGG-EDA-biotin ligated to IL-1R1.
Reaction Scheme 2: Reaction scheme for the ligation of 5(6) carboxyfluorescein to IL-1ra. 1)
IL-1R1 containing a C-terminal sortase tag and polyhistidine tag. 2) Triglycine ethylenediamine
5(6) carboxyfluorescein. 3) GGG-EDA-fluorescein ligated to IL-1R1.
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Reaction Scheme 3: Reaction scheme for the ligation of 5(6) carboxyfluorescein to IL-1ra. 1)
IL-1ra containing a C-terminal sortase tag. 2) Triglycine ethylenediamine 5(6)
carboxyfluorescein. 3) GGG-EDA-fluorescein ligated to IL-1ra.
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Appendencies
Figure A1. 5000 pM IL-1R1 + 500 pM IL-1ra-FL. Black: IL-1ra-FL, Green: Complex run 1,
Brown: Complex run 2, Blue: Complex run 3, Pink: Baseline.
Figure A2. 2500 pM IL-1R1 + 500 pM IL-1ra-FL. Black: IL-1ra-FL, Green: Complex run 1, Brown:
Complex run 2, Blue: Complex run 3, Pink: Baseline.



















































Figure A3. 1250 pM IL-1R1 + 500 pM IL-1ra-FL. Black: IL-1ra-FL, Green: Complex run 1,
Brown: Complex run 2,Blue: Complex run 3, Pink: Baseline.
Figure A4. 625 pM IL-1R1 + 500 pM IL-1ra-FL. Black: IL-1ra-FL, Green: Complex run 1,
Brown: Complex run 2, Blue: Complex run 3, Pink: Baseline.


















































Figure A5. 312 pM IL-1R1 + 500 pM IL-1ra-FL. Black: Complex run 1, Pink: Complex run 2,
Blue: Complex run 3.
Figure A6. 156 pM IL-1R1 + 500 pM IL-1ra-FL. Black: IL-1ra-FL, Green: Complex run 1,
Brown: Complex run 2, Blue: Complex run 3, Pink: Baseline.





















































Figure A7: 75 pM IL-1R1 + 500 pM IL-1ra-FL. Black: IL-1ra-FL, Green: Complex run 1,
Brown: Complex run 2, Blue: Complex run 3, Pink: Baseline.
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